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Human CD81 T Cell Responses to EBV EBNA1:
HLA Class I Presentation of the (Gly-Ala)±Containing
Protein Requires Exogenous Processing
simplex virus encodes an immediate-early protein, ICP47,
and human cytomegalovirus (HCMV) a late protein, US6,
which block peptide transport by interacting with the
cytosolic and ER aspects, respectively, of the TAP com-
plex (FruÈ h et al., 1995; Hill et al., 1995; Ahn et al., 1997;
Neil Blake,* Steven Lee,* Irina Redchenko,*
Wendy Thomas,* Neil Steven,* Alison Leese,*
Patty Steigerwald-Mullen,² Michael G. Kurilla,²
Lori Frappier,³ and Alan Rickinson*§
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Hengel et al., 1997). In addition, HCMV encodes otherUniversity of Birmingham
ER-resident proteins, one of which (immediate-earlyBirmingham B15 2TA
US3) acts to retain MHC class I molecules at this siteUnited Kingdom
(Ahn et al., 1996; Jones et al., 1996), while others (US11²Department of Pathology and Microbiology
and US2) subsequently transport the retained moleculesUniversity of Virginia
back to the cytosol (Wiertz et al., 1996a, 1996b). For bothCharlottesville, Virginia 22901
of these viruses, the effect of the processing blockade³Department of Medical Genetics
is to divert the human CTL response toward epitopesand Microbiology
derived from virion structural proteins, that is, antigensUniversity of Toronto
delivered into the cytosol at the initiation of infection,Toronto, Ontario M5S 1A8
when the antigen processing pathway is still intact (Rid-Canada
dell et al., 1991; Tigges et al., 1992). With HCMV, such
diversion is exaggerated by the ability of the virion matrix
protein pp65 to further protect the immediate-early anti-Summary
gen IE1 from processing by posttranslational modifica-
tion (Gilbert et al., 1996).Epstein-Barr virus (EBV)±induced cytotoxic T lympho-
By contrast, immediate-early and early proteins en-cyte (CTL) responses have been detected against
coded during lytic replication of Epstein-Barr virusmany EBV antigens but not thenuclear antigen EBNA1;
(EBV), the prototype human g herpesvirus, appear to bethis has been attributed to the presence of a glycine-
highly immunogenic to the CTL response (Steven etalanine repeat (GAr) domain in the protein. Here we
al., 1997), implying that this agent may have evolveddescribe the isolation of human CD81 CTL clones rec-
different strategies of immune evasion operating at dif-ognizing EBNA1-specific peptides in the context of
ferent times during its life cycle. In this context, EBVHLA-B35.01 and HLA-A2.03. Using these clones, we
has a unique capacity to colonize the host through theshow that full-length EBNA1 is not presented when
virus-driven clonal expansion of latently infected B cells.expressed endogenously in target cells, whereas the
This latent growth-transforming infection is also stronglyGAr-deleted form is presented efficiently. However,
immunogenic and elicits CD81 CTL responses directedwhen supplied as an exogenous antigen, the full-
against a range of latent cycle proteins, most particularlylength protein can be presented on HLA class I mole-
the EBV nuclear antigens EBNAs 3A, 3B, and 3C butcules by a TAP-independent pathway; this may explain
also less frequently against EBNA2, EBNA-LP, and thehow EBNA1-specific CTLs are primed in vivo.
latent membrane proteins LMP1 and LMP2 (Khanna et
al., 1992; Murray et al., 1992; Rickinson and Moss, 1997).
To date, however, no such responses have been de-Introduction
tected against EBNA1, the virus genome maintenance
protein and the only viral protein expressed in all inVirus-specific CD81 cytotoxic T lymphocytes (CTLs) rec-
vitro forms of EBV latency and in all virus-associatedognize short viral peptides presented on the cell surface
malignancies (Rickinson and Kieff, 1996). The work ofas a complex with major histocompatibility (MHC) class
Levitskaya et al. (1995) has suggested that the presenceI molecules. Viral proteins synthesized in the cytosol are
of a glycine-alanine repeat (GAr) domain of more thandegraded, primarily by the proteasome system, and the
200 amino acids within the EBNA1 primary sequenceresultant peptides are translocated into the endoplas-
prevents the protein from being presented to the CD81mic reticulum (ER) by the transporter associated with
CTL repertoire. Thus, insertion of an immunodominantantigen processing (TAP). Binding of high-affinity pep-
epitope from EBNA3B (also known as EBNA4) into thetides to nascent MHC class I molecules in the ER gener-
full-length EBNA1 sequence, and insertion of the GAr
ates stable MHC class I±peptide complexes which then
domain into full-length EBNA3B, in both cases markedly
move via the ER±Golgi network to the cell surface for
reduced epitope-specific CTL recognition of these chi-
presentation to the CD81 T cell repertoire (York and
meric proteins when expressed from recombinant vac-
Rock, 1996).
cinia vectors.
Various mechanisms have been identified whereby
Prompted by these important findings, we began a
viruses might evade such CTL recognition; some of the
series of experiments to determine the extent to which
more interesting recent examples have come from hu-
this GAr-mediated silencing of EBNA1 as a CTL target
man herpesviruses of the a and b subfamilies. Herpes
antigen is absolute in natural EBV infections. Here we
report the isolation of EBNA1 epitope±specific CTLs
from three virus-immune individuals; confirm that the§To whom correspondence should be addressed (e-mail: williamsd
@cancer.bham.ac.uk). GAr domain does block presentation of these epitopes
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Figure 1. Screening of EBV-Specific CTL
Clones from Donors RT and IM52
(A) Schematic representation of the full-
length EBNA1 protein and of the glycine±
alanine±deleted form E1DGA. The GAr do-
main (striped box) and nuclear localization
signal (nls, shaded boxes) are highlighted.
Amino acid coordinates refer to the EBNA1
sequence in the reference EBV strain, B95.8.
(B) Autologous target cells, infected over-
night with a recombinant vaccinia virus ex-
pressing the indicated EBV latent protein,
were labeled with (51Cr)O4 and used in stan-
dard chromium release assays with CTL
clones derived from in vitro LCL stimulation
of peripheral blood mononuclear cells from
donors RTand IM52. Specific clones are illus-
trated to indicate the range of CTL responses
generated. Results are expressed as percent-
age specific lysis seen in assays conducted
at effector:target ratios of between 2:1 and 5:1.
from an endogenously expressed EBNA1 protein; and EBNA1, since in the presence of the GAr domain, the
only viable recombinants carry the EBNA1 gene in re-identify an alternative pathway whereby the GAr-con-
taining protein can be presented to the CD81 CTL verse orientation; vaccinia-mediated expression of the
full-length protein could be achieved under the controlsystem.
of a T7 promoter, but this required coinfection with a
secondvaccinia expressing T7 RNA polymerase (MurrayResults
et al., 1992). The availability of the vacc-E1DGA recombi-
nant therefore allowed us to screen for EBNA1-specificIsolation of EBNA1-Specific CTL Clones
and Identification of Target Epitopes CTL reactivities without the requirement for a helper
virus and without the potential interference in antigenWe first constructed a recombinant vaccinia virus that
could express a GAr-deleted form of EBNA1 (E1DGA; processing mediated by the GAr domain.
In a first series of experiments, memory CTLs wereFigure 1A) from the vaccinia P7.5 promoter. Constructs
of this kind have never been obtained with full-length reactivated from healthy EBV-seropositive donors by
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B27.05-restricted epitope in EBNA 3C (c63), and an
A2.01-restricted epitope in LMP2 (c10) plus novel
clones, of which c16 is an example, specifically recog-
nizing E1DGA-expressing targets. These E1DGA-spe-
cific clones were in a minority, but, overall, such reactivi-
ties have been generated from donor RT on three
independent occasions by in vitro stimulation with the
autologous B95.8 virus±transformed LCL.
In a parallel series of experiments, T cell clones were
established from the blood of patients with infectious
mononucleosis (IM) undergoing primary EBV infection.
Again one of six patients studied, IM52 (HLA-A11, -A30,
-B13, -B35.01, -C6) yielded clones that recognized
E1DGA-expressing targets; representative results are
shown for one such clone, c66, in Figure 1B (right col-
umn) along with other clones from the same individual
recognizing an A11-restricted epitope in EBNA3B (c52),
a C6-restricted epitope in EBNA3C (c45), and a rare,
as yet poorly characterized, epitope in EBNA-LP (c27)
(Steven et al., 1996; N. S., unpublished data).
The E1DGA-reactive clones from donor RT and IM52
were then tested in further assays designed to identify
their HLA restriction element and viral epitope peptide.
In experiments of the kind illustrated in Figure 2A, repre-
sentative clones from donor RT were assayed on the
autologous and on HLA-matched allogeneic LCL targets
with or without vaccinia-mediated E1DGA expression.
There was no lysis of the EBV-transformed LCLs per se
(data not shown) and no lysis after their infection with
Figure 2. An E1DGA-Specific CTL Clone from Donor RT Is Re- an irrelevant vaccinia (vacc-EBNA3B); however, vacc-
stricted through HLA-B35.01 and Recognizes the Minimal Epitope E1DGA infection induced specific killing both of the au-
Peptide HPVGEADYFEY (EBNA1 407±417) tologous and of B35.01-matched LCLs (Figure 2A), indi-
(A) CTL clone RT c28.90 (recognized as E1DGA-specific in screening cating CTL restriction through the HLA-B35.01 allele.
assays of the kind illustrated in Figure 1) was tested in a chromium
To identify the cognate viral epitope, E1DGA-specificrelease assay against vacc-E1DGA±infected LCL targets matched
clones such as RT c28.90 were then screened againstat particular HLA class I loci, as indicated. As a control, the LCL
synthetic peptides (15-mers overlapping 10) spanningtargets were infected with a vaccinia vector expressing EBNA3B
(vE3B). Note that the range of targets also included the TAP-negative the entire unique sequence of EBNA1. Using a visual
T2:B35.01 cell line either infected with vacc-E1DGA or vE3B as assay of T cell±T cell killing for the initial screen, two
described above, or preexposed to the EBNA1 407±417 epitope overlapping peptides representing amino acids 403±417
peptide at 2 3 1028 M or to DMSO alone as a control.
and 408±422 of the B95.8 strain EBNA1 sequence ap-(B) RT c28.90 was tested against autologous LCL cells preincubated
peared to contain the antigenic epitope. Smaller pep-with the indicated molar concentration of synthetic peptides from
tides from within this region were then titrated for theirwithin the EBNA1 region 406±417. The minimal epitope was defined
as HPVGEADYFEY (EBNA1 407±417). ability to sensitize autologous LCL targets to CTL recog-
All results are expressed as percentage specific lysis seen in a nition in standard chromium release assays. As shown
standard chromium release assay at an effector:target ratio of 5:1. by the representative results in Figure 2B, this identified
the 11-mer peptide EBNA1 407±417 (HPVGEADYFEY)
as the minimal epitope sequence. This accords well with
stimulating peripheral blood lymphocytes with irradi- the B35.01 consensus motif identified by sequencing
ated cells of the autologous EBV-transformed B lym- eluted peptides, having a proline at position 2 and a
phoblastoid cell line (LCL), followed by limiting dilution tyrosine at the C-terminus (Rammensee et al., 1995).
cloning. Individual CD81 T cell clones were then tested Precisely similar results were obtained using the
for evidence of EBV antigen±specific cytotoxicity by E1DGA-reactive clones from IM52, indicating that these
screening on autologous target cells expressing E1DGA were also B35.01 restricted and specific for the EBNA1
or one of the other virus latent proteins from recombi- 407±417 epitope (data not shown). Identification of HLA-
nant vaccinia vectors. Significantly, one of the first six B35.01 as the restriction element allowed us to carry
healthy donors tested, donor RT (HLA-A2.01, -A24.02, out an additional experiment using as target cells
-B27.05, -B35.01, -C2.02, -C4), gave evidence of an T2:B35.01, an HLA-B35.01 transfectant of the TAP-neg-
E1DGA-specific response. Figure 1B (left column) illus- ative T2 cell line (Salter et al., 1985; Takiguchi et al.,
trates the four types of clonal reactivity detectable in 1994); this formally demonstrated that the processing
the CTL memory of this donor. These included pre- and presentation of endogenously expressed E1DGA
viously identified (Rickinson and Moss, 1997) reactivi- was TAP dependent. Thus, RT c28.90 effectors recog-
nized T2:B35.01 cells when preloaded with the EBNA1ties to a B35.01-restricted epitope in EBNA3A (c58), a
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vacc-E1DGA and only if the cells expressed the HLA-
A2.03 allele (Figure 3A). Screening the panel of EBNA1
peptides in a visual T cell±T cell killing assay firstshowed
that the epitope lay within the amino acid region 568±
586, and subsequent titration assays with smaller pep-
tides from the region identified the 9-mer sequence
VLKDAIKDL (EBNA1 574±582) as the minimal epitope
(Figure 3B).
Effect of the GAr Domain on the CTL Recognition
of Endogenously Expressed Antigen
Using the above CTL clones, we were able to test the
effect of the GAr domain upon the processing of natural
CD81 T cell epitopes within the EBNA1 primary se-
quence. As illustrated in Figures 4A and 4B, the first
experiments of this kind used target LCLs either infected
with a control vaccinia (vacc-TK) or infected with vacc-
E1DGA or coinfected with vacc-E1 (expressing full-
length EBNA1) plus the vacc-T7 helper virus. All of the
B35.01-restricted, EBNA1 407-417±specific clones tested
from donor RT and IM52 gave strong lysis of vacc-
E1DGA±infected targets, approaching that seen with tar-
get cells preexposed to the synthetic epitope peptide. In
addition, these effectors consistently recognized vacc-
E1/vacc-T7±coinfected targets at levels that, though
lower, were always significantly above the background
seen for targets infected with the control vaccinia; repre-
sentative results fromone such clone, RT c28,are shown
in Figure 4A. Similar results were also consistently ob-
served with the A2.03-restricted CTL clones from NPC4
recognizing the EBNA1 574-582 epitope, although abso-
lute levels of lysis were always lower with these ef-
fectors; representative results from two such clones,
Figure 3. E1DGA-Specific CTL Clones from Donor NPC4 Are Re-
c11 and c16, are shown in Figure 4B.stricted through HLA-A2.03 and Recognize the Minimal Epitope
The problems inherent in using vaccinia vectors toPeptide VLKDAIKDL (EBNA1 574±582)
express full-length EBNA1 were highlighted, however,(A) CTL clone NPC4 c11 (recognized as E1DGA-specific in screening
when we checkedthe EBNA1 species being synthesizedassays of the kind illustrated in Figure 1) was tested in a chromium
release assay against vacc-E1DGA±infected LCL targets matched in vacc-E1/vacc-T7±coinfected cells. Figure 4C shows
at particular HLA class I loci as indicated. As a control, the same an immunoblot of protein extracts from vacc-E1DGA±
LCL targets were infected with a vaccinia vector expressing EB- infected and from vacc-E1/vacc-T7±coinfected cells,
NA3C (vE3C).
probed with a monoclonal antibody (MAb) 1H4±1 recog-(B) A second E1DGA-specific clone, NPC c16, was tested against
nizing a motif in the unique C-terminal domain of EBNA1.autologous LCL target cells preincubated with the indicated molar
This confirms that vacc-E1DGA expresses a singleconcentration of synthetic peptides within the EBNA1 region 573±
582 or with an equivalent dilution of DMSO as the `no peptide' EBNA1 species whose size, approximately 52 kDa, cor-
control. The minimal epitope was defined as VLKDAIKDL (EBNA1 responds to that expected for the GAr-deleted polypep-
574±582). tide. However, the vacc-E1 recombinant expresses a
All results are expressed as percentage specific lysis seen in a
heterogeneous pool of EBNA1 species ranging from fullstandard chromium release assay at an effector:target ratio of 5:1.
length (approximately 80 kDa) down to a size equivalent
to that of E1DGA itself.
In light of these findings, we elected to study the CTL407±417 peptide but not when infected with vacc-
E1DGA (Figure 2A). recognition of full-length versus GAr-deleted EBNA1
proteins using a different viral vector system in whichIn subsequentwork, we screened theperipheral blood
and/or tumor-infiltrating lymphocytes of three patients the presence or absence of a GAr domain did not influ-
ence the generation of standard recombinants. Thuswith EBV genome±positive nasopharyngeal carcinoma
(NPC) for evidence of virus-specific CTL reactivities. An- replication-deficient recombinant adenoviruses RAdE1
and RAdE1DGA were constructed expressing the rele-alyzing the T cell clones induced by autologous LCL
stimulation in vitro identified one patient, NPC4 (HLA- vant EBNA1 sequences from the CMV immediate early
promoter. As illustrated in Figure 5C, immunoblotting ofA2.03, -A2.07, -B38, -B46.01, -C1, -C7.02), in whom the
tumor-infiltrating lymphocyte population contained an infected cell extracts with the MAb1H4±1 confirmed that
RAdE1DGA expressed the 52 kDa GAr-deleted productE1DGA-reactive component. Figure 3 presents the rele-
vant data from two such clones, c11 and c16. These while RAdE1 (unlike the corresponding vaccinia recom-
binant) expressed a single polypeptide whose positionagain recognized LCL targets only after infection with
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on the gel was equivalent to that of the full-length EBNA1
protein found in LCL cells. These viruses were then used
to sensitize target cells for cytotoxicity assays.
Representative results are shown in Figures 5A and
5B from assays involving B35.01-positive LCL targets
and EBNA1 epitope±specific effectors RT c28.28 and
IM52 c66. Target cells expressing the GAr-deleted form
of EBNA1 were lysed almost as strongly as cells pre-
loaded with the epitope peptide. Now, however, target
cells expressing full-length EBNA1 as a single species
were never recognized above the background levels
shown by the control RAd35-infected targets. This pat-
tern of results was obtained on several independent
occasions of testing with a number of different CTL
clones.
CTL Recognition of Exogenously Loaded EBNA1
If full-length endogenously expressed EBNA1 is not pro-
cessed for presentation to CD81 T cells, there must be
another route whereby such epitope-specific responses
are elicited in vivo. The fact that exogenously delivered
antigens can under certain circumstances be presented
via the MHC class I pathway (Rock, 1996) led us to
examine this as a possibility.
The initial studies were carried out using fragments
of EBNA1 expressed in bacteria as fusions with maltose-
binding protein (MBP); the fusion protein E1CD contains
an EBNA1 fragment (residues 323±450) that includes the
B35.01 epitope 407-417, whereas fusion protein E1NX
contains two linked EBNA1 fragments (residues 8±39
and 420±641) but lacks the B35.01 epitope. Neither fu-
sion protein carries the GAr domain; indeed it was not
possible to express larger GAr-containing fragments of
EBNA1 in a bacterial expression system. In an initial
experiment B35.01-positive LCL cells were incubated
in serum-free medium for 12 hr at 378C in the presence
of E1CD, E1NX, or MBP, and then washed extensively,
labeled with chromium, and used as targets in a stan-
dard cytotoxicity assay; parallel targets from the same
LCL were incubated with the synthetic epitope peptide
or with dimethyl sulfoxide (DMSO) solvent as a control,
and then likewise washed extensively before use in the
assay. Overnight (12 hr) incubation with the epitope-
containing E1CD fusion protein clearly sensitized these
cells to recognition by EBNA1-specific effectors (Figure
served at effector:target ratios of 5:1 (solid bars) and 2:1 (striped
bars).
(B) CTL clones NPC4 c16 (solid bars) and c11 (striped bars) were
tested against an A2.03-matched target LCL infected with the same
vaccinia recombinants as in (A). Control targets included the same
LCL preexposed to the EBNA1 574±582 epitope peptide at 2 3 1028
M or to DMSO alone. Results are expressed as percentage specific
lysis observed at an effector:target ratio of 5:1 for both clones.
(C) Immunoblot of protein extracts from human fibroblasts either
mock-infected or infected at 10 moi with the following recombinant
Figure 4. Partial Recognition of vacc-E1/vacc-T7 Coinfected Target vaccinia viruses: vacc-TK (vTK2), vacc-E1 plus vacc-T7 (vE1/vT7),
Cells by E1DGA-Specific CTL Clones from Donors RT and NPC4 vacc-E1DGA (vE1DGA), orvacc-E1 alone (vE1). Cells wereharvested
(A) CTLclone RTc28 was tested against a standard B35.01-matched 20 hr after infection and extracts (105 cell equivalents/track) resolved
target LCL that had been infected with vacc-E1DGA (vE1DGA), with on a 7.5% SDS-PAGE gel along with reference extracts (106 cell
vacc-TK (vTK2) as a control or coinfected with vacc-E1 (vE1) and equivalents/track) from the EBV-positive B95.8 LCL and from the
vacc-T7 (vT7) viruses. Control targets included the same LCL preex- BJAB cell line as controls. The blot was probed with the EBNA1-
posed to the EBNA1 407±417 epitope peptide at 2 3 1028 M or to specific MAb 1H4±1 and developed using enhanced chemilumines-
DMSO alone. Results are expressed as percentage specific lysis cence (Amersham).
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6A), with optimal lysis seen at fusion protein concentra-
tions of 1027 M and greater (Figure 6B). Control experi-
ments were then carried out to ensure that this E1CD-
mediated sensitization reflected active processing of
the exogenously added protein and not just the direct
binding to B35.01 molecules of preexisting peptide frag-
ments within the fusion protein preparation.
Thus when the E1CD-containing medium was spun
through a Centricon C10 column with a 10 kDa molecular
weight cut-off, the flow-through (which would contain
any small peptide contaminants) did not sensitize cells
to lysis, whereas the retained protein fraction was as
effective as the original preparation (data not shown).
Furthermore, varying the time of incubation with the
fusion protein before the assay showed that E1CD-
mediated sensitization required overnight exposure,
whereas the synthetic epitope peptide was effective
within 45 min (Figure 6C). The fusion protein was not
required throughout the whole 12 hr period, however,
since a short (2 hr) exposure followed by washing and
overnight incubation in fresh medium also sensitized
target cells to specific lysis (data not shown). Last,
whereas peptide sensitization remained optimal when
carried out at 48C, sensitization by E1CD required incu-
bation at 378C (Figure 6C), suggesting that active uptake
and processing of the fusion protein were involved.
In the final series of assays, again using CTL clones
reactive to the B35.01-restricted epitope EBNA1 407-
417, we sought to determine whether full-length EBNA1
(containing the GAr domain) could be handled as an
exogenous antigen and presented on HLA class I mole-
cules as above. For this it was necessary to use proteins
expressed in the baculovirus system, namely full-length
EBNA1 (b1-641) and two smaller GAr-negative EBNA1
fragments, b330-641 containing the B35.01 epitope and
b451-641 lacking the epitope. These preparations were
tested in parallel with the E1CD, E1NX, and MBP bacteri-
ally expressed proteins for their ability to sensitize a
standard B35.01-positive LCL to CTL recognition by
overnight incubation.
Representative assays using two CTL clones, RT c83
and RT c84, are illustrated inFigure 7A. There was strong
sensitization mediated by b330-641, almost to the levels
shown by the E1CD fusion protein and by the synthetic
epitope peptide itself. More important, the cells preincu-
bated with the full-length b1-641 protein were also con-
sistently recognized, showing levels of lysis lower than
seen for b330-641±treated targets but significantly
higher than the background values seen for control tar-
gets preincubated with b451±641. Sensitization with
these baculovirus-expressed proteins required similar
conditions to those already identified for E1CD (data
not shown). This series of assays was then extended
to include the TAP-negative T2:B35.01 cell line as the
Figure 5. Nonrecognition of RAdE1-Infected Target Cells by source of target cells. The pattern of results obtained,
E1DGA-Specific CTL Clones from Donors RT and IM52
(A) CTL clone RT c28.28 and (B) CTL clone IM52 c66 were tested
against a standard B35.01-matched target LCL that had been in-
fected with recombinant adenoviruses expressing E1DGA (RAdE1- (C) Immunoblot of protein extracts from A549 cells infected at 200
DGA), EBNA1 (RAdE1), or the control RAd35. Control targets in- moi with RAdE1, RAdE1DGA, or the control RAd35. Cells were har-
cluded the same LCL preexposed to the EBNA1 407±417 epitope vested 20 hr after infection and extracts (2 3 105 cell equivalents/
peptide at 2 3 1028 M or to DMSO alone. Results are expressed as track) resolved by 7.5% SDS-PAGE along with B95.8 LCL and BJAB
percentage specific lysis observed at effector:target ratios of 5:1 reference extracts (106 cell equivalents/track); the blot was then
(solid bars) and 2:1 (striped bars). probed with MAb 1H4±1 as described for Figure 4C.
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Figure 6. EBNA1 Epitope±Specific CTL
Clones Recognize B35.01-Matched LCL Tar-
get Cells Exogenously Loaded with an
EBNA1/MBP Fusion Protein
(A) Target cells were preincubated in 1 ml
AIM-V serum free medium for 12 hr at 378C
with bacterially expressed MBP or with the
MBP fusion proteins E1NX or E1CD at 2 3
1027 M and then washed extensively and
used in a chromium release assay with CTL
clone RT c28.58 specific for the EBNA1 407±
417 epitope. As controls, target cells were
similarly preexposed for 12 hr to the EBNA1
peptide 407±417 at 2 3 1027 M or to DMSO
alone.
(B) Target cells were preloaded for 12 hr at
378C with different concentrations of E1CD
and then washed extensively and used in a
chromium release assay with CTL clone RT
c83 specific for the EBNA1 407±417 epitope.
Peptide- and DMSO-treated control targets
are as in (A).
(C) Target cells were preloaded with E1CD at
2 3 1027 M in 1 ml of AIM-V media for the
indicated time period and then washed ex-
tensively before being used in a chromium
release assay with CTL clone RT c83. As con-
trols, target cells were preexposed for 45 min
to the EBNA1 epitope peptide 407±417 at
2 3 1028 M or to DMSO alone.
(D) Target cells were preincubated for 12 hr
with MBP or E1CD at 2 3 1027 M in 1 ml
AIM-V media either at 378C or at 48C, before extensive washing and use in a chromium release assay with CTL clone RT c83. As controls,
target cells were preexposed for 12 hr at 48C to the EBNA1 epitope peptide 407±417 at 2 3 1028 M or to DMSO alone.
Results throughout are expressed as percentage specific lysis seen at an effector:target ratio of 5:1.
illustrated in Figure 7B, was very similar to that seen gave CD81 CTL clones that recognized a specific combi-
nation of EBNA1 epitope peptide and HLA class I±restrict-with a standard TAP-positive LCL. Thus, preexposure
of T2:B35.01 cells to E1CD or to b330-641 efficiently ing allele (Figures 1±3). Thus, donors RT and IM52 both
yielded CTLs recognizing the 11-mer epitope EBNA1sensitized the cells to the EBNA1 epitope±specific CTL
clones RT c83 and RT c28.90. Moreover, the full-length 407±417 in the context of B35.01, and NPC4 yielded
CTLs recognizing the 9-mer epitope EBNA1 574±582 inprotein b1-641 again mediated significant sensitization,
producing levels of lysis clearly above control values. the context of A2.03. In the case of the B35.01-restricted
CTLs, their inability to recognize vacc-E1DGA±infected
cells of the T2:B35.01 line formally proved that the en-Discussion
dogenously expressed E1DGA protein was being pro-
cessed and presented via the conventional TAP-depen-Earlier work from several laboratories has shown that
EBV-induced CTL responses are detectable against dent pathway. The circumstantial evidence strongly
supports the contention that these are authentic EBV-most of the eight virus-coded latent cycle proteins but
apparently not against EBNA1 (Gavioli et al., 1992; induced responses and not rare examples of cross-reac-
tivity, that is, CTLs induced by some other agent butKhanna et al., 1992; Murray et al., 1992; Tamaki et al.,
1995). A possible explanation came from Levitskaya et fortuitously recognizing an epitope in the EBNA1 se-
quence. First, it would be remarkable if such cross-al. (1995), who, working with chimaeric antigens ex-
pressed from vaccinia vectors, found that molecules reactivity were to explain two independent examples of
EBNA1 epitope±specific lysis when such a mechanismcontaining the GAr domain were to a large extent pro-
tected from presentation via the HLA class I pathway. has not been substantiated for the response toany other
EBV target antigen; we have, for instance, never de-In the present report we show (1) that CD8 1 HLA class
I±restricted CTL responses to EBNA1 epitopes are in tected cross-reactive recognition of any EBV epitope
in autologous LCL-stimulated T cell preparations fromfact detectable in humans; (2) that such CTLs recognize
only target cells endogenously expressing the GAr- EBV-seronegative individuals (Rickinson and Moss,
1997). Furthermore, recognition of the above EBNA1deleted and not the full-length form of EBNA1; and (3)
that, when delivered as an exogenous antigen, the full- epitopes was detected down to the 10212 and 10210 M
peptide concentrations respectively in titration assays,length protein can be processed and presented on HLA
class I molecules via an alternative TAP-independent values that lie within the range of endpoints observed for
immunodominant peptide epitopes in other EBV latentpathway.
When screened for EBNA1-specific reactivities using cycle proteins (Burrows et al., 1992a; Gavioli et al., 1993;
Lee et al., 1995, 1997). Finally, and most significantly,vacc-E1DGA±infected targets, 3 of 15 individuals tested
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Figure 7. Exogenously Loaded EBNA1 Is
Processed in a TAP-Independent Manner
(A) B35.01-matched LCL target cells were
preincubated with either bacterially ex-
pressed proteins (MBP, E1NX, or E1CD) or
baculovirus-expressed proteins (b451-641,
b1-641, or b330-641) at 2 3 1027 in 1 ml of
AIM-V serum for 12 hr at 378C and then
washed extensively and used in chromium
release assays with CTL clones RT c83 (top)
and RT c84 (bottom) specific for the EBNA1
407±417 epitope.
(B) TAP-negative T2:B35.01 target cells were
preincubated with either bacterially ex-
pressed proteins (MBP, E1NX, or E1CD) or
baculovirus expressed proteins (b451-641,
b1-641, or b330-641), washed, and used
in chromium release assays exactly as de-
scribed for Figure 7A, with CTL clones RTc83
(top) and RT c28.90 (bottom) specific for the
EBNA1 407±417 epitope.
Results are expressedas percentage specific
lysis seen at an effector:target ratio of 5:1.
Note that each assay included as control tar-
gets the same target line preexposed as de-
scribed above to the EBNA1 407±417 epitope
at 2 3 1028 M or to DMSO alone. nt, not
tested.
one of thesources of theCTL clones, IM52, was a patient genome during viral replication (Ball, 1987), resulting in
varying lengths of the GAr domain at the nucleic acidin the acute phase of primary infection, when the virus-
induced CTL response is at its peak (Steven et al., 1996); level. We could not discount the possibility, therefore,
that the low-level lysis of vacc-E1±infected targetsanother was the lymphocytic infiltrate of an EBV-positive
malignancy, NPC, in which every tumor cell expresses stemmed from the processing of vector-encoded EBNA1
molecules with deletions in the GAr domain. Unambigu-EBNA1 in the absence of the other EBNAs (Rickinson
and Kieff, 1996). ous results were obtained only upon switching to the
recombinant adenoviral system (Grunhaus and Horwitz,Using these EBNA1 epitope±specific CTLs to study
processing of the native protein,we observed significant 1992), where both full-length and GAr-deleted EBNA1
could be expressed from viral vectors of equivalent con-lysis of vacc-E1/vacc-T7 coinfected target cells ex-
pressing full-length EBNA1, although at levels much struction (Figure 5). These assays now proved that the
pesence of the GAr domain in native EBNA1 can indeedlower than seen for vacc-E1DGA±infected targets (Fig-
ure 4). This result was consistent with the original find- offer the endogenously expressed protein efficient pro-
tection from the TAP-dependent processing pathway.ings on CTL recognition of a vaccinia-expressed refer-
ence antigen with or without GAr insertion (Levitskaya Such findings nevertheless highlighted a paradox. If
the native virus-coded EBNA1 protein is protected fromet al., 1995) and suggested that the GAr domain can
indeed inhibit processing but not completely. However, processing, how are EBNA1 epitope±specific responses
elicited in vivo? There is no evidence for the existencethe experiments are complicated by the finding that,
even using plaque-purifiedstocks of the vacc-E1 recom- of GAr-negative strains of EBV in the human population
(Hennessy and Kieff, 1983; Falk et al., 1995), and in factbinant, EBNA1 is expressed in the vaccinia system as
a smear of protein species ranging from full-length (80 we were able to isolate the resident EBV from two of
our three CTL donors, RT and IM52, and in both caseskDa) down to the size of the GAr-deleted product (52
kDa) (Figure 4C). This smearing is highly unusual and confirm that it encoded a GAr-positive EBNA1 protein
of standard size (data not shown). A possible solutioncontrasts with the marked stability of the native EBV-
coded EBNA1 in vaccinia-infected LCL cells (data not was suggested tous by recent work showing that exoge-
nous antigens can be processed for presentation onshown). We believe that such results are not a reflection
of proteolytic breakdown from the full-length protein, MHC class I molecules, especially if supplied in a partic-
ulate form that encourages their uptake by phagocytosisbut rather of heterogeneity in the size of the EBNA1
coding sequence within the vacc-E1 virus preparation or macropinocytosis (Kovacsovics-Bankowski et al.,
1993; Pfeifer et al., 1993; Ulmer et al., 1994; Norbury etitself. This heterogeneity is not due to plaque variation,
since the same pattern was observed with independent al., 1995; Rock, 1996). We therefore asked whether LCL
cells, which are often used as surrogate antigen-pre-virus isolates even after attempts at further plaque purifi-
cation (M. G. K., unpublished data), but probably arises senting cells in in vitro assays, could process exoge-
nously added EBNA1 and present the derived epitopesthrough homologous recombination of the vaccinia virus
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calf serum, 100 IU/ml penicillin, 100 mg/ml streptomycin, and 2 mMon HLA class I molecules. The results clearly showed
L-glutamine. Primary human fibroblasts were established from smallthat such processing could occur with exogenously sup-
skin biopsies and passaged in RPMI 1640 medium supplementedplied fragments of EBNA1 produced either as a MBP
as described above. The EBNA1-specific rat MAb 1H4±1 (GraÈ sser
fusion protein in bacteria or from a baculovirus vector et al., 1994), which recognizes a motif in the unique C-terminal
(Figures 6 and 7). Numerous controls indicated that pre- domain (F. GraÈ sser, unpublished data), was a kind gift from F.
GraÈ sser (University of Homburg-Saar, Germany). Peptides were syn-sentation required active processing of the exogenous
thesized by standard fluorenyl-methoxycarbonyl chemistry (Altaprotein by cells and was not attributable to peptide con-
Bioscience, University of Birmingham, United Kingdom) and dis-taminants preexisting in the preparation.
solved in DMSO, and their concentrations determined by biuretMore important, a purified preparation of full-length
assay.
EBNA1 produced in the baculovirus system (b1±641)
could also be processed and presented on HLA class CTL Cloning
I molecules, albeit somewhat less efficiently than the EBV-specific CTL clones were derived from healthy EBV-seroposi-
tive donors and from patients with IM by autologous LCL stimulationcorresponding b330-641 EBNA1 fragment (Figure 7A).
and limiting dilution cloning, using published procedures (Steven etThe ability to handle full-length EBNA1 clearly distin-
al., 1996; Lee et al., 1997). Samples from patients with NPC wereguishes this pathway of exogenous antigen processing
kindly provided by P. Johnson (Department of Clinical Oncology,
from the conventional route taken by endogenously ex- Prince of Wales Hospital, Shatin, Hong Kong). T cell clones were
pressed proteins. A second important distinction be- isolated from peripheral blood lymphocytes as described above for
tween the two pathways became apparent when the healthy donors, and from tumor infiltrating lymphocytes as follows.
The biopsy was finely minced with scalpel blades, and the cellsexperiments were extended to include the T2:B35.01
released into suspension were cultured in 96-well round-bottomline as a source of antigen-presenting cells (Figure 7B).
plates in growth medium containing 30% MLA 144 supernatant andThis showed that presentation of exogenously loaded
recombinant interleukin-2 (100 IU/ml). After 7 days, cells were refed
EBNA1, whether full-length protein or a fragment, oc- with this medium and stimulated with autologous LCL (irradiated at
curred via a TAP-independent pathway. The nature of 4000 rad; responder-to-stimulator ratio 40:1). Cells were refed again
this pathway remains to be determined, but it is worth on days 14 and 21 and then cloned by limiting dilution as described
above.noting that other reports have also described the TAP-
independent processing of exogenous antigen by LCL
CTL Assayscells (Liu et al., 1995; Schirmbeck et al., 1995). Recent
EBV-specific CTL clones were identified, using a chromium releasework by Levitskaya et al. (submitted) indicates that GAr-
assay, by their ability to lyse targets expressing individual EBVgenes
mediated protection from the TAP-dependent pro- from recombinant vaccinia vectors. Targets were incubated with
cessing pathway is mediated at the level of proteasome 50±100 mC of (51Cr)O4 for 90 min, washed, and incubated with CTL at
breakdown, and it will be important to determine known effector-to-target ratios in a standard 5 hr chromium release
assay. The percentage specific lysis was calculated as (release bywhether the TAP-independent pathway identified here
CTL 2 spontaneous release) 3 100/(total released in 1% SDS 2involves the proteasome at any stage.
spontaneous release). For experiments using recombinant vacciniaWe propose that CD81 T cell responses against
viruses, target cells were infected with virus for 90 min at a multiplic-
EBNA1 epitopes are induced in vivo through uptake of ity of infection (moi) of 10 and then incubated in growth medium for
the exogenous protein by professional antigen-pre- an additional 15 hr prior to labeling with chromium. For experiments
senting cells. In this context, there must be a continued with recombinant adenoviruses, target cells were infected at a moi
of 200 for 90 min, followed by incubation in growth medium for 15supply of EBNA1 protein released in vivo since, of all of
hr before labeling with chromium.the virus latent proteins, EBNA1 is the only one against
To identify viral epitopes, EBNA1-specific clones were first testedwhich antibodies are consistently maintained in healthy
in a visual T cell±T cell killing assay (Burrows et al., 1992b) using
virus carriers (Henle et al., 1987), and recent work has overlapping 14- and 15-mer synthetic peptides representing the
also identified EBNA1-specific CD41 T cells in virus- entire unique sequence of the EBNA1 protein. Minimal epitopes
immune individuals (Khanna et al., 1995, 1997). How- were mapped in chromium release assays using smaller peptides
from within the region of interest. Peptides were added to targetever, we emphasize that, while CD81 CTLs are induced
cells at known dilutions, using equivalent dilutions of peptide-freeagainst EBNA1 epitopes,such effectors will not be capa-
DMSO as a control. In cytotoxicity assays involving exogenous load-ble of recognizing naturally infected cells expressing
ing of protein, unless otherwise stated target cells were incubated
the full-length GAr-positive protein. If, as other work at 378C with 2 3 1027 M protein in 1 ml AIM-V serum-free medium
suggests (Tierney et al., 1994; Chen et al., 1995), EBV (Life Technologies) for thespecified time period,or with the synthetic
persists by adopting forms of latency in which EBNA1 epitope peptide as a positive control. Preloaded target cells were
then washed extensively and labeled with chromium for 90 minis present in the absence of the other EBNAs, protection
before being used in a standard chromium release assay.of the full-length protein from endogenous processing
would offer such cells a means of avoiding detection in
Construction of Plasmids and Recombinant Virusesthe immunocompetent host.
E1DGA was generated by polymerase chain reaction (PCR) dele-
tional mutagenesis from the plasmid pBS:E1 (which contains EBV
genomic fragment 107,823±110,280 spanning the EBNA1 codingExperimental Procedures
sequence; for nucleotide coordinates see Baer et al., 1984). The 59
and 39 regions flanking the GAr domain were amplified separatelyCell Lines, Antibodies, and Peptides
LCLs were established and maintained as described (Steven et al., using the following primers: E1A: 59-GAATCATGTCTGACGAGGGG
CCAG-39 (59 base 107,945) and E1Br: 59-ACCTCCTGCTCCTGTTCC1996); the T2:B35.01 line, established by stable transfection of T2
cells (Salter et al., 1985) with an HLA B35.01 cDNA (Takiguchi et al., ACGGTG-39 (39 base 108,205), producing a 284bp 59 fragment,
and E1C: 59-ACAGGAGCAGGAGGTGGAGGCCGG-39 (39 base1994), was kindly provided by M. Takiguchi (University of Tokyo,
Japan). The 293 human kidney (ATCC CRL 1573) and A549 human 108,936) and E1Dr: 59-GGGGTCCAGTGCTTGGGCCTTCTC-39 (39 base
109,277), producing a 388bp 39 fragment. Both fragments werelung carcinoma (ATCC CCL 185) cell lines were passaged in Dulbec-
co's modified Eagle's medium supplemented with 10% (v/v) fetal mixed and reamplified with primer E1A and E1Dr, and the resulting
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657 bp fragment was digested with BspE1 and PflMI and ligated into was generated using the BaculoGold system (Pharmingen, San
Diego, CA) and EBNA1 protein expressed and purified as describedthe similarly digested pBS:E1, generating the plasmid pBS:E1DGA
(corresponding to a deletion of EBNA1 codons 92±323). Vacc- previously (Goldsmith et al., 1993). All preparations were checked
by Coomassie staining of SDS-PAGE gels and shown to containE1DGA was constructed as described previously for recombinant
vaccinia viruses expressing EBNAs 2, 3A, 3B, 3C, and LP and LMPs a single protein species of the expected size with no detectable
breakdown products.1 and 2 (Murray et al., 1992). Vacc-E1 expressing full-length EBNA1
and the control vaccinia vacc-TK have been described previously
(Murray et al., 1992). RAds expressing EBNA1 and E1DGA were Acknowledgments
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lished: Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A.,
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12616±12621.
